<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578158</url>
  </required_header>
  <id_info>
    <org_study_id>LUMHS/REC/894</org_study_id>
    <nct_id>NCT04578158</nct_id>
  </id_info>
  <brief_title>Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19</brief_title>
  <official_title>A Prospective, Randomized, Open-labelled, Controlled Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With Diagnosis of COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaquat University of Medical &amp; Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaquat University of Medical &amp; Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the&#xD;
      treatment of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-labelled and controlled study aimed to investigate the adjuvant&#xD;
      benefits of Quercetin Phytosome in community-based subjects with confirmed SARS-CoV-2&#xD;
      infection (by RT-PCR). The study has two arms. In one arm the subjects will receive standard&#xD;
      COVID-19 care as per the hospital/Physician guidelines, whereas in the other arm the subjects&#xD;
      will receive standard COVID-19 care + Quercetin Phytosome. The treatment will continue for 30&#xD;
      days. It is proposed that Quercetin Phytosome will boost the natural immunity of the subjects&#xD;
      and will help in preventing the COVID-19 disease progression i.e preventing the need of&#xD;
      hospitalisation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">June 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 28, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with COVID-19 disease progression</measure>
    <time_frame>From day 1 to day 30</time_frame>
    <description>Percentage of subjects who require hospitalisation</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive the standard COVID-19 care as per the hospital physician guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quercetin Phytosome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive standard COVID-19 care + Quercetin Phytosome</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard COVID-19 care</intervention_name>
    <description>Patients will receive standard covid-19 care as per the hospital/physician guidelines</description>
    <arm_group_label>Quercetin Phytosome</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Quercetin Phytosome</intervention_name>
    <description>Patients will receive a daily dose of 400 mg of oral Quercetin Phytosome</description>
    <arm_group_label>Quercetin Phytosome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adult patients with positive SARS-CoV-2 RT-PCR on nasal swab or deep respiratory&#xD;
             sample, diagnosed with moderate-to-severe Respiratory Acute Syndrome (ARDS) within 10&#xD;
             days, according to Berlin definition:&#xD;
&#xD;
          -  New or worsening of respiratory symptoms within a week of a known clinical insult&#xD;
&#xD;
          -  Radiological imaging (CT, RX, ultrasound) of bilateral pulmonary opacity not fully&#xD;
             explained by pouring, lobular or pulmonary atelectasis, or nodules&#xD;
&#xD;
          -  Respiratory failure not fully explained by heart failure or water overload (after&#xD;
             exclusion of hydrostatic causes of edema in the absence of risk factors by objective&#xD;
             assessment, for example ultrasound)&#xD;
&#xD;
          -  PaO2/FiO2 &lt; 300 mmHg with PEEP (or CPAP) ≥ 5 cm H20&#xD;
&#xD;
          -  Increase of the value of PCR&#xD;
&#xD;
          -  Need or not need for mechanical ventilation and/or CPAP&#xD;
&#xD;
          -  Patients who have signed informed consent. In the event of impossibility/inability to&#xD;
             obtain informed consent due to the clinical framework (e.g. patients over the age of&#xD;
             18 sedated and treated for acute respiratory failure and subsequent mechanical&#xD;
             ventilation) it will be carried out assuming the patient's consent until contrary will&#xD;
             is manifest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with proven hypersensitivity or allergic reaction to quercetin&#xD;
&#xD;
          -  Manifest contrary will&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prof. Dr. Ikram Din Ujjan</last_name>
    <phone>+ 92 333 2276556</phone>
    <email>ikramujjan@lumhs.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Prof. Dr. Saeed Khan</last_name>
    <phone>+ 92 333 2276556</phone>
    <email>saeed.khan@duhs.edu.pk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liaquat University Hospital</name>
      <address>
        <city>Jāmshoro</city>
        <state>Sindh</state>
        <zip>76090</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Ikram Din Ujjan</last_name>
      <email>ikramujjan@lumhs.edu.pk</email>
    </contact>
    <contact_backup>
      <last_name>Prof. Dr. Saeed Khan</last_name>
      <phone>+ 92 333 2276556</phone>
      <email>saeed.khan@duhs.edu.pk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <results_reference>
    <citation>Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol. 2020 Jun 19;11:1451. doi: 10.3389/fimmu.2020.01451. eCollection 2020. Review.</citation>
    <PMID>32636851</PMID>
  </results_reference>
  <results_reference>
    <citation>Abian O, Ortega-Alarcon D, Jimenez-Alesanco A, Ceballos-Laita L, Vega S, Reyburn HT, Rizzuti B, Velazquez-Campoy A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int J Biol Macromol. 2020 Dec 1;164:1693-1703. doi: 10.1016/j.ijbiomac.2020.07.235. Epub 2020 Aug 1.</citation>
    <PMID>32745548</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu X, Raghuvanshi R, Ceylan FD, Bolling BW. Quercetin and Its Metabolites Inhibit Recombinant Human Angiotensin-Converting Enzyme 2 (ACE2) Activity. J Agric Food Chem. 2020 Nov 25;68(47):13982-13989. doi: 10.1021/acs.jafc.0c05064. Epub 2020 Nov 12.</citation>
    <PMID>33179911</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>January 30, 2021</last_update_submitted>
  <last_update_submitted_qc>January 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaquat University of Medical &amp; Health Sciences</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Ikram Din Ujjan, MBBS, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19, Quercetin Phytosome, Anti-inflammatory, Immunomodulatory, Respiratory distress</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quercetin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

